Lexicon Pharmaceuticals
LXRX
106 hedge funds and large institutions have $417M invested in Lexicon Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 25 increasing their positions, 31 reducing their positions, and 14 closing their positions.
178% more capital invested
Capital invested by funds: $150M → $417M (+$267M)
114% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 14
53% more call options, than puts
Call options by funds: $2.26M | Put options by funds: $1.48M
16% more funds holding
Funds holding: 91 → 106 (+15)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11.09% less ownership
Funds ownership: 97.33% → 86.24% (-11%)
19% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$20.9M |
| 2 |
AG
Artal Group
Luxembourg
|
+$20.9M |
| 3 |
PA
Pinnacle Associates
New York
|
+$2.87M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.58M |
| 5 |
Millennium Management
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.2M |
| 2 |
Lazard Asset Management
New York
|
-$2.52M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.01M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.88M |
| 5 |
BlackRock
New York
|
-$1.84M |
LXRX Hedge Fund Activity: Q4 2020 in Review
106 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2020, worth a combined $417M — up 178% from $150M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new LXRX positions and 14 closed out — a net gain of 16 holders — while 25 added to existing stakes and 31 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $20.9M. The largest seller was Federated Hermes, cutting an estimated $3.2M.
- 106 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2020, up from 91 in Q3 2020.
- Funds reported $417M of Lexicon Pharmaceuticals stock for Q4 2020, up 178% quarter-over-quarter.
- 30 funds opened new Lexicon Pharmaceuticals positions in Q4 2020 and 14 closed out, a net change of +16 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2020 was BVF Inc, an estimated $20.9M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2020 was Federated Hermes, an estimated $3.2M sold.
Based on aggregated 13F filings for Q4 2020.